Shionogi-ViiV Healthcare To Start Phase III Trial For HIV Drug

21st Jul 2010 09:19

LONDON (Dow Jones)--Shionogi-ViiV Healthcare LLC Wednesday said it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572, or 572, into Phase III clinical trials. MAIN FACTS: -This decision is based on promising results from two Phase IIb trials, SPRING-1 and VIKING. -Trials explored the efficacy of '572 in treatment-naive HIV subjects as well as in treatment-experienced subjects resistant to raltegravir. Further study in Phase III is necessary to determine conclusively the safety, efficacy and resistance profile of '572. -By Ian Walker, Dow Jones Newswires; 44-20-7842-9296; [email protected] (END) Dow Jones Newswires July 21, 2010 04:19 ET (08:19 GMT)

Top Risers

Share	Price	Change
Huddled Group (HUD)	0.85	24.14%
Eurasia Mining (EUA)	2.80	19.15%
Genincode (GENI)	0.725	16%
Medpal AI (MPAL)	5.25	14.13%
Light Science Technologies (LST)	0.875	12.9%

Top Fallers

Share	Price	Change
Catenai Plc (CTAI)	0.0575	-39.47%
Petra Diamonds (PDL)	2.60	-26.14%
Focus Xplore (FOX)	0.019	-22.45%
Litigation Cap. (LIT)	0.301	-20.12%
Abrdn Property (API)	1.52	-15.56%

Top By Volume

Share	Price	Volume
Ethernity Net (ENET)	0.0019	1,922,336,250
Forgent (FORG)	0.0115	591,087,829
Premier African Minerals (PREM)	0.0044	313,776,718
Focus Xplore (FOX)	0.019	253,421,870
Bezant Resources PLC (BZT)	0.11	246,929,868

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.